Shares of AbbVie Inc. tumbled 8% Thursday, after the biopharmaceutical company missed first-quarter profit expectations, as some of its newer drugs missed their revenue targets while blockbuster Humira lost ground to biosimilars.
The stock was on track for its biggest one-day percentage decline since March of 2020 and was second worst performer on the S&P 500 after Align Technology Inc. ALGN
Humira,…
Read the full article here
